舍曲林联合奎硫平治疗伴焦虑的抑郁症患者对照研究

Clinical control study of sertraline combined with quetiapine in treatment of depressive patients with anxiety symptoms

目的:探讨低剂量奎硫平对舍曲林治疗伴焦虑的抑郁症患者的辅助疗效和安全性。方法:将64例伴焦虑的抑郁症患者随机分为舍曲林合并奎硫平组(合并奎硫平组)32例和单用舍曲林组32例。采用汉密尔顿焦虑量表(HAMA)和汉密尔顿抑郁量表(HAMD)及治疗中出现的症状量表(TESS)于治疗前和治疗1、2、4、8周末分别评定疗效和不良反应。结果:从治疗第1周末起各时点,两组HAMD和HAMA评分及减分率的差异有统计学意义(P<0.05或P<0.01)。合并奎硫平组的有效率为75%,舍曲林组有效率为50%,两组间差异有统计学意义(P<0.05),两组不良反应差异无统计学意义(P>0.05)。结论:舍曲林合并小剂量奎硫平治疗伴焦虑的抑郁症患者的疗效优于单用舍曲林,安全性相似。

Objective： To explore the efficacy and safety of low-dose quetiapine augmentation of sertraline on depression with anxiety symptoms. Method：64 depressive patients with anxiety symptoms were randomly assigned to the two groups：a low dose of quetiapine plus ongoing sertraline（n=32） and sertraline alone（n=32）.The Hanmilton depressive scale （HAMD）,Hanmilton anxiety scale （HAMA） and treatment emergent symptoms scale （TESS） were adopted to evaluate the efficacy and adverse reactions at baseline and after 1,2,4 and 8 week treatment. Results：There were significant differences on the scores of HAMD and HAMA between the two groups at each time point from 1st weekend after treatment.（P0.05 or P0.01）.The response rates of augmented treatment group was 75% and mono-therapy group was 50%,augmented treatment group demonstrated higher efficacy than mono-therapy group （P0.05）.The adverse reactions in both groups showed no significant difference.（P0.05）. Conclusion： Quetiapine may be a useful and safe adjunct to sertraline in treatment of depression with anxiety symptoms.